What are Xell’s major offerings in terms of products and services for the life sciences industry?
Xell AG was founded back in 2009 as a spin-off from the Cell Culture Technology lab at Bielefeld University. Our goal was to make the lab’s proprietary technology – rational, lean-designed and chemically defined cell culture media (CD-CCM) – accessible to both the global biopharma industry and the biotech community. The Cell Culture Technology lab at Bielefeld University can even trace its experience and refinement of animal cell culture technology way back to 1989, a time when technologies were being developed to express proteins from mammalian cells economically.
Staying true to our origins, this particular scientific approach will always remain an inherent part of Xell’s DNA. Proof of this lies in our analytical capabilities, particularly the analysis of the spent media samples that we have continuously developed in parallel with the ever-increasing demand for CDCCM on the global market. This makes Xell the ideal partner for biopharma, biotechnological and feed and food companies.
For more than a decade now, our experience and industry-leading knowledge has allowed us to build an extensive, versatile and all-around superior product and service portfolio for any client or application utilising CHO, HEK, Hybridoma, BHK, MDCK, Vero or other human cell lines. We have established long-lasting client relationships with partners of varying sizes based all over the globe. What’s more, we are also represented by various agents and distributors who support our ambition to strategically increase our market share outside of Europe.
How was the FY20-21 for the company? What growth does Xell foresee in 2021?
Continue reading your story on the app
Continue reading your story in the magazine
Rare diseases policy outlines challenges sans solutions
There is no substantial data on the number of people suffering from rare diseases in India and the data that is available is from tertiary care hospitals. The lack of epidemiological data on rare diseases makes it a herculean task to determine the prevalence and burden of rare diseases, hence hampering the definition of rare diseases in the Indian context.
PSA launches community mental-health digital platform
The Principal Scientific Adviser (PSA) to the Government of India Prof. K VijayRaghavan has virtually launched ‘MANAS’ App to promote wellbeing across age groups.
“India should have a vibrant clinical research community who can advise drug developers”
The Indian Society for Clinical Research (ISCR), an association of clinical research professionals, has announced the appointment of Dr Sanish Davis as its President for the term 202123.
MALARIA DENGUE TB PLAY SECOND FIDDLE to COVID - 19
Although India has worked relentlessly towards developing innovative testing solutions for COVID-19 throughout last year, the timely detection of a number of other infectious diseases has been sidelined. In India, the range and burden of infectious diseases such as tuberculosis, malaria, filariasis, leprosy, HIV infection, typhoid, hepatitis etc., are enormous. In fact, inadequate containment of the vector has resulted in recurrent outbreaks of dengue fever and re-emergence of chikungunya virus disease and typhus fever. If India can develop more than 20 different diagnostic tests or devices in a single year to fight COVID-19, many more such innovations can be brought to effectively detect other infections looming in our country.
Govt fast-tracks emergency approvals for foreign-made COVID-19 vaccines
The matter of augmenting the basket of vaccines available for fighting the pandemic as well as accelerating the pace and coverage of domestic vaccination programmes was discussed recently at the 23rd meeting of the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC).
Wipro Focuses On Transforming Vaccine Safety Assessment
Bengaluru -based IT firm Wipro has announced a partnership with Hyderabad-based Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI).
Dr. Reddy's Launches Sputnik V Vaccine In India
Dr. Reddy’s Laboratories announced that the first consignment of imported doses of the Sputnik V vaccine that landed in India on May 1, 2021, received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021. As part of a limited pilot, the soft launch of the vaccine has commenced and the first dose of the vaccine was administered in Hyderabad on May 14, 2021.
“Made in India products need an ecosystem for commercialisation of innovations”
Established in 1998, Ernakulam-based Agappe Diagnostics is one of the rapidly growing companies in the in vitro diagnostic (IVD) industry in India, having a wide range of products in the pre-analytical and analytical segment. Focused on research, design, and production of clinical chemistry reagents and instrument, Agappe has over 1000 distributors and holds a significant place in the global original equipment manufacturer (OEM) business. The company currently has a workforce of more than 600 employees spread across sectors such as R&D, manufacturing, sales, support and operations. In conversation with BioSpectrum, Thomas John, Managing Director, Agappe Diagnostics, Ernakulam shares his strategies and plans for the company’s growth in the long run.
Vocalising pain is a must
Women have unique health issues. In fact, some of the health issues that affect both men and women can affect women very differently.
“India should focus on innovating drugs and molecules to emerge as a global leader”
The Organisation of Pharmaceutical Producers of India (OPPI) has elected S Sridhar as its next President for a period of two years, effective from February 15, 2021. He takes over from Sharad Tyagi, Former Managing Director, Boehringer Ingelheim India Pvt Ltd. Sridhar is currently serving as the Managing Director of Pfizer Limited and is heading Pfizer Inc’s commercial business in India. Sridhar has been a member of the Executive Committee of OPPI for the past six years and has also chaired its Finance and Taxation Work Group. He is a strong voice of healthcare transformation in the country and was the chair of FICCI’s Pharma Committee till recently. In conversation with BioSpectrum, S Sridhar talks about making a difference to patients, the industry and the country via this new role.